BioSpace News Archive

BAQSIMI is expected to be available in U.S. pharmacies within one month

Bristol-Myers Squibb Company (NYSE: BMY) today announced that Part 2 of the Phase 3 CheckMate -227 trial did not meet the primary endpoint of overall survival (OS) with Opdivo® (nivolumab) plus chemotherapy versus chemotherapy in patients with first-line non-squamous non-small cell lung cancer (NSCLC), regardless of PD-L1 status (HR 0.86; 95% CI 0.69-1.08).

Bristol-Myers Squibb Company (NYSE: BMY) today announced that Part 1a of the Phase 3 CheckMate -227 trial evaluating Opdivo® (nivolumab) plus low-dose Yervoy® (ipilimumab) met the co-primary endpoint of overall survival (OS), demonstrating a superior benefit versus chemotherapy in first-line non-small cell lung cancer (NSCLC) patients whose tumors express PD-L1 ≥1%.

Acerus Pharmaceuticals Corporation announced that NATESTO® is now on formulary and covered nationwide by a leading national pharmacy benefit manager in the United States.

Genomma Lab Internacional, S.A.B. de C.V. announced its results for the second quarter ended June 30, 2019.

Drawbridge Health, a healthcare technology company streamlining the blood draw process for both patients and healthcare providers, announced it has completed a strategic international financing.

Bio-Rad Laboratories, Inc. announces that the Delaware District Court granted Bio-Rad’s motion for permanent injunction against 10X Genomics from making any sales of infringing products to new customers and granting Bio-Rad’s request for supplemental damages and pre- and post-judgement interest.

PD-L1+ NK cells may prove to be another important immune effector cell for checkpoint inhibitor-based cancer immunotherapy

Canadian Food Inspection Agency has confirmed the presence of emerald ash borer in Oromocto, New Brunswick.

July 24, 2019 16:59 UTC Laminate Medical Technologies announces enrollment of first forearm patients in pivotal trial of the VasQ device TEL AVIV, Israel--( BUSINESS WIRE )-- Laminate Medical Technologies (Laminate) has announced the enrollment of their first forearm fistula patients in their US pivotal trial of the VasQ™ device. VasQ is an implanted blood vessel external support intended to promote maturation and reduce the high primary failure rate of surgically created fistulas